Loading...
•
Sep 30, 2021
Castle Biosciences Q3 2021 Earnings Report
Announced third quarter 2021 results, with revenue growing by 54% over the prior year quarter.
Key Takeaways
Castle Biosciences announced strong Q3 2021 results, with a 54% increase in revenue compared to the same period in 2020, reaching $23.5 million. The company also reported a total gene expression profile test reports delivered of 7,727. They are on track to achieve 2021 total revenue guidance of $89-93 million.
Q3 2021 revenue grew by 54% over the prior year quarter to $23.5 million.
Total gene expression profile test reports delivered in the third quarter of 2021 were 7,727, compared to 4,779 in the same period of 2020.
Gross margin for the quarter ended Sept. 30, 2021, was 77.9%.
Company is on track to achieve 2021 total revenue guidance of $89-93 million.
Forward Guidance
Castle Biosciences raised its guidance for anticipated total revenue in 2021 to $89-93 million. The Company believes it will meet the guided range.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...